Precision Medicine

The explosion of genetic and molecular medicine has produced mountains of options and evidence. Conversely, there is often an alarming lack of evidence. This is where we come in.

We help you manage the flood of tests and drugs that emerge in this category daily. Accessed through the Hayes Knowledge Center, our comprehensive Precision Medicine solution focuses on thousands of genetic, genomic, and molecular diagnostic tests and precision medicine therapies addressing the questions our clients most frequently ask:

  • Will testing change patient management for this indication?
  • If so, what tests and/or therapies should I use?
  • Should we cover testing and/or therapies?
  • Can we manage these services internally?

Cologuard (Exact Sciences Corp.)

Focus of the Report: This report examines the analytical validity, clinical validity, and clinical utility of the Cologuard stool DNA test for the qualitative detection of colorectal neoplasia–associated DNA markers and for the presence of occult hemoglobin in human stool, which may indicate the presence of colorectal cancer (CRC) or advanced a…

read more

Clinical Utility of Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) in Patients with Intellectual Disability (ID)

This report evaluates the clinical utility of whole genome sequencing (WGS) and whole exome sequencing (WES) in patients with a primary phenotype of intellectual disability (ID). In general, ID may be associated with other neurological disorders, various genetic syndromes, and autism spectrum disorders. However, this report focuses on patients whose primary phenotype of conce…

read more

VeriStrat for Prognostic Use in Patients with Advanced NSCLC (Biodesix Inc.)

The report evaluates the analytical validity, clinical validity, and clinical utility of the VeriStrat test, a liquid biopsy-based proteomic test that identifies a chronic inflammatory immune response indicative of aggressive disease in patients with advanced non-small cell lung cancer (NSCLC) and is intended to provide prognostic information to assist physicians with patient…

read more

ChemoFx Assay (Helomics)

This report evaluates the analytical validity, clinical validity, and clinical utility of the ChemoFx test, an in vitro patient tumor–derived cell culture assay that determines how cancer cells may respond to chemotherapeutic agents in order to help guide physicians’ treatment decisions in patients with gynecologic cancer.

read more

Epi proColon (Epigenomics Inc.)

Focus of the Report: This report evaluates the analytical validity, clinical validity, and clinical utility of the Food and Drug Administration–approved Epi proColon blood-based liquid biopsy test, for the detection of methylated Septin 9 (SEPT9) as cell-free circulating DNA, that is intended to screen for colorectal cancer (CRC) in average-ris…

read more

FirstSightCRC (CellMax Life)

The report evaluates the analytical validity, clinical validity, and clinical utility of the FirstSightCRC test, a liquid biopsy test that detects and analyzes circulating tumor cells (CTCs) and is intended to predict the likelihood of having precancerous adenomatous polyps or colorectal cancer (CRC) in patients eligible for CRC screening.

read more